The controlled release of tilmicosin from silica nanoparticles

Drug Development and Industrial Pharmacy

Volumn 37, Issue 6, 2011, Pages 714-718

  Song, Meirong ^a   Li, Yanyan ^b   Fai, Cailing ^a   Cui, Shumin ^a   Cui, Baoan ^a  

^a HENAN AGRICULTURAL UNIVERSITY   (China)

^b HENAN INSTITUTE OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

controlled release; diffusion; nanomaterials; Silica nanoparticles; tilmicosin

Indexed keywords

NANOPARTICLE; PHOSPHATE BUFFERED SALINE; SILICON DIOXIDE; TILMICOSIN;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG ADSORPTION; IN VITRO STUDY; THERMOGRAVIMETRY; ZETA POTENTIAL;

ANTI-BACTERIAL AGENTS; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG STABILITY; KINETICS; NANOPARTICLES; PARTICLE SIZE; SILICON DIOXIDE; THERMOGRAVIMETRY; TIME FACTORS; TYLOSIN;

EID: 79955964964     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.538059     Document Type: Article

References (25)

1. Susan LHG, Tucker DT, Robin SR. (1993). A study of tilmicosin residues in milk following subcutaneous administration to lactating dairy cows. Can Vet J 34:619-621.
2. Han C, Qi CM, Zhao BK, Cao J, Xie SY, Wang SL, Zhou WZ. (2009). Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J Vet Pharmacol Ther 32:116-123.
3. Nickerson SC, Owens WE, Fox LK, Scheifinger CC, Shryock TR, Spike TE. (1999). Comparison of tilmicosin and cephapirin as therapeutics for Staphylococcus aureus mastitis at dry-off. J Dairy Sci 82:696-703. (Pubitemid 129552364)
4. Ziv G, Shem-Tov M, Glickman A, Winkler M, Saran A. (1995). Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther 18:340-345.
5. Ramadan A. (1997). Pharmacokinetics of tilmicosin in serum and milk of goats. Res Vet Sci 62:48-50. (Pubitemid 27214439)
6. Jordan WH, Byrd RA, Cochrane RL, Hanasono GK, Hoyt JA, Main BW, Meyerhoff RD, Sarazan RD. (1993). A review of the toxicology of the antibiotic MICOTIL 300. Vet Hum Toxicol 35:151-158. (Pubitemid 23091277)
7. McGuigan MA. (1994). Human exposures to tilmicosin (MICOTIL). Vet Hum Toxicol 36:306-308.
8. Van Donkersgoed J, Dubeski PL, VanderKop M, Aalhus JL, Bygrove S, Starr WN. (2000). The effect of animal health products on the formation of injection site lesions in subprimals of experimentally injected beef calves. Can Vet J 41:617-622.
9. Clark C, Woodbury M, Dowling P, Ross S, Boison JO. (2004). A preliminary investigation of the disposition of tilmicosin residues in elk tissues and serum. J Vet Pharmacol Ther 27:385-387. (Pubitemid 39482246)
10. Milan S, Stanislav Ž. (2001). Lipid-based vehicle for oral drug delivery. Biomed Papers 145:17-26.
11. Radin S, Chen T, Ducheyne P. (2009). The controlled release of drugs from emulsified, sol gel processed silica microspheres. Biomaterials 30:850-858.
12. Prokopowicz M. (2009). Correlation between physicochemical properties of doxorubicin-loaded silica/polydimethylsiloxane xerogel and in vitro release of drug. Acta Biomater 5:193-207.
13. Guenther U, Smirnova I, Neubert RH. (2008). Hydrophilic silica aerogels as dermal drug delivery systems-dithranol as a model drug. Eur J Pharm Biopharm 69:935-942.
14. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. (2008). Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60:1278-1288.
15. Xu W, Gao Q, Xu Y, Wu D, Sun Y. (2009). pH-Controlled drug release from mesoporous silica tablets coated with hydroxypropyl methylcellulose phthalate. Mater Res Bull 44:606-612.
16. Lin CX, Qiao SZ, Yu CZ, Ismadji S, Lu G.Q. (2009). Periodic mesoporous silica and organosilica with controlled morphologies as carriers for drug release. Micropor Mesopor Mat 117: 213-219.
17. Musa EB, Ala'a E, Iyad R, Mayyas AR, Adnan B. (2008). A novel super disintegrating agent made from physically modified chitosan with silicon dioxide. Drug Dev Ind Pharm 34:373-383.
18. Unger K, Rupprecht H, Valentin B, Kircher W. (1983). The use of porous and surface modified silica as drug delivery and stabilizing agents. Drug Dev Ind Pharm 9:69-91. (Pubitemid 13149439)
19. Branka R, Mirjam G, Mirjana G, Karine P, Franciose F. (2010). Dual influence of colloidal silica on skin deposition of vitamins C and E simultaneously incorporated in topical microemulsions. Drug Dev Ind Pharm 36:852-860.
20. Manja A, Pirjo K, Ilkka K, Juha K, Antti Y. (1999). In vitro release behavior of toremifene citrate from sol-gel processed sintered silica xerogels. Drug Dev Ind Pharm 25:955-959.
21. Song YH, Bai XH, Li YJ. (2005). Determination of tilmicosin by ultraviolet spectrophotometry. Shanxi Med Univ 36:71-73.
22. Zhu YF, Shi JK, Li YS, Chen HR, Shen WH, Dong XP. (2005). Hollow mesoporous spheres with cubic pore network as a potential carrier for drug storage and its in vitro release kinetics. J Mater Res 20: 54-61.
23. Serra L, Doménech J, Peppas NA. (2006). Drug transport mechanisms and release kinetics from molecularly designed poly(acrylic acid-gethylene glycol) hydrogels. Biomaterials 27:5440-5451. (Pubitemid 44109896)
24. Manuel D, Kevin EW, Herbert AK, Julie AW, Gary DC, Eddie VT, Jeffery TV, Fred TC, John LO, Earl EO, Satoshi O. Synthesis and antimicrobial evaluation of 20-deoxo-20-(3,5-dimethyl-1- piperidinyl)desmycosin desmycosin (tilmicosin, EL-870) and related cyclic amino derivatives. J Antibiot 62:1253-1267.
25. Costa P, Lobo JMS. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123-133. (Pubitemid 32288781)